Out-licensing
- Out-licensing
- View
Transdermal Rivastigmine
Mechanism of action
Full description
Rivastigmine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type and for the management of mild to moderate dementia associated with Parkinson's disease.
Amarin has developed a Rivastigmine TDS using its liquid-in-liquid adhesive technology, and concluded a Phase I study using Exelon Patch as comparator in 2011.
Development status
Patent information
A patent application was filed in Europe, USA, Canada, Brazil, Mexico and Argentina.
Type of business relationship sought
The product has been licensed to Asofarma (Argentine) under non-exclusive terms for Argentine and Brazil.
Amarin is seeking to license this product for USA, Europe and other territories.
Related reports
Licensing contact
Company details
Amarin is engaged in the development of innovative pharmaceutical products using its proprietary topical and transdermal drug delivery technologies and know-how.
View profileRelated technologies
- Butylcholinesterase-Binding Compounds for Monitoring and Inhibiting the Progression of Alzheimer's Disease (TID - 42)
- Multiactivity glutamic acid derivatives and their potential usefulness in the treatment of Alzheimer’s disease.
- Radiotracers for Imaging Cannabinoid Sub-Type1 (CB1) Receptor
- 1,4,5-dibenzo[b,f] thiadiazepinez 5,6-dihydro as neuroprotective agents, useful for the treatment of alzheimer’s and other neurodegenerative diseases
- Improved Pharmacokinetic Profiles of methylphenidate for ADHD (09-22)
Related categories
- Industry sector
- Drug delivery
- Pharmaceutical / Generics
- Pharmaceutical / Prescription
- Therapeutic target
- Central Nervous System / Age-related disorders (other)
- Central Nervous System
- Central Nervous System / Neurodegenerative disorders
- Central Nervous System / Neurological
- Central Nervous System / Psychiatric
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us